Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | PKM | P14618 | 3/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | CRHBP | P24387 | 1/20 | 0.56 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31183018 | 1.00 | MEN1 (0.68) | MEN1KMT2APKMCYP1A2CYP2D6 | |
| SCHEMBL3059715 | 0.86 | MEN1 (0.64) | MEN1KMT2APKMCYP1A2CYP2D6 | |
| SCHEMBL2900203 | 0.85 | MEN1 (0.66) | MEN1KMT2APKMCYP1A2CYP2D6 | |
| Iodide SCHEMBL2892303 | 0.84 | MEN1 (0.64) | MEN1KMT2APKMCYP1A2CYP2D6 | |
| Iodide SCHEMBL2900263 | 0.84 | MEN1 (0.64) | MEN1KMT2APKMCYP1A2CYP2D6 | |
| SCHEMBL31174258 | 0.82 | MEN1 (0.59) | MEN1KMT2APKMCYP1A2CYP2D6 | |
| SCHEMBL2017366 | 0.82 | POLB (0.64) | MEN1KMT2APKMCYP1A2CYP2D6 | |
| SCHEMBL11811576 | 0.82 | PKM (0.62) | MEN1KMT2APKMCYP1A2CYP2D6 | |
| SCHEMBL8292031 | 0.82 | CYP1A2 (0.64) | MEN1KMT2APKMCYP1A2CYP2D6 | |
| SCHEMBL4739771 | 0.82 | MEN1 (0.71) | MEN1KMT2APKMCYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117101725-A | Immobilized manganese catalyst and preparation method and application thereof | 浙江工业大学 | 2023-11-24 | — | — | CN | disclosed |
| CN-109641863-B | Intermediate for synthesizing carfilzomib and synthesis of pharmaceutically acceptable salt thereof | 美国安进公司 | 2023-10-20 | — | — | CN | disclosed |
| US-11708341-B2 | Synthesis of (S)-2-amino-4-methyl-((R)-2-methyloxirane-2-yl)-pentan-1-one and pharmaceutically acceptable salts thereof | AMGEN INC. | 2023-07-25 | — | — | US | disclosed |
| US-11708341-B2 | Synthesis of (S)-2-amino-4-methyl-((R)-2-methyloxirane-2-yl)-pentan-1-one and pharmaceutically acceptable salts thereof | AMGEN INC. | 2023-07-25 | — | — | US | disclosed |
| US-11708341-B2 | Synthesis of (S)-2-amino-4-methyl-((R)-2-methyloxirane-2-yl)-pentan-1-one and pharmaceutically acceptable salts thereof | AMGEN INC. | 2023-07-25 | — | — | US | disclosed |
| US-20210284617-A1 | Synthesis of (S)-2-Amino-4-Methyl-((R)-2-Methyloxirane-2-Yl)-Pentan-1-One and Pharmaceutically Acceptable Salts Thereof | AMGEN INC. | 2021-09-16 | — | — | US | disclosed |
| US-20210284617-A1 | Synthesis of (S)-2-Amino-4-Methyl-((R)-2-Methyloxirane-2-Yl)-Pentan-1-One and Pharmaceutically Acceptable Salts Thereof | AMGEN INC. | 2021-09-16 | — | — | US | disclosed |
| EP-3494108-B1 | SYNTHESIS OF (S)-2-AMINO-4-METHYL-1-((R)-2-METHYLOXIRANE-2-YL)-PENTAN-1-ONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | AMGEN INC (US) | 2020-10-28 | — | — | EP | disclosed |
| EP-3494108-B1 | SYNTHESIS OF (S)-2-AMINO-4-METHYL-1-((R)-2-METHYLOXIRANE-2-YL)-PENTAN-1-ONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | AMGEN INC (US) | 2020-10-28 | — | — | EP | disclosed |
| EP-3494108-A1 | SYNTHESIS OF (S)-2-AMINO-4-METHYL-1-((R)-2-METHYLOXIRANE-2-YL)-PENTAN-1-ONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | Amgen Inc. (US) | 2019-06-12 | — | — | EP | disclosed |
| US-20030073710-A1 | Compounds useful for treatment or prevention of disease mediated by alpha-2B-adrenoceptor | OY JUVANTIA PHARMA LTD (FI) | 2003-04-17 | — | — | US | disclosed |
| WO-2003008387-A1 | COMPOUNDS USEFUL FOR TREATMENT OR PREVENTION OF DISEASE MEDIATED BY ALPHA-2B-ADRENOCEPTOR | OY JUVANTIA PHARMA LTD (FI) | 2003-01-30 | — | — | WO | disclosed |
| WO-2002076440-A2 | METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES | ELAN PHARMACEUTICALS, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| US-6150526-A | Piperidine derivative having renin inhibiting activity | HOFFMANN-LA ROCHE INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6051712-A | PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS | HOFFMANN-LA ROCHE INC. (US) | 2000-04-18 | — | — | US | disclosed |
| EP-0863875-A1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | F. HOFFMANN-LA ROCHE AG (CH) | 1998-09-16 | — | — | EP | disclosed |
| WO-1997009311-A1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | F. HOFFMANN-LA ROCHE AG (CH) | 1997-03-13 | — | — | WO | disclosed |
| US-3988229-A | Stabilized photopolymerizable polymeric compositions containing a photoinitiator and a nitrone derivative | EASTMAN KODAK COMPANY (US) | 1976-10-26 | — | — | US | disclosed |
| US-3962056-A | MOLDING, COATING | EASTMAN KODAK COMPANY (US) | 1976-06-08 | — | — | US | disclosed |
| US-3962055-A | MOLDING, COATING | EASTMAN KODAK COMPANY (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073710-A1 | Compounds useful for treatment or prevention of disease mediated by alpha-2B-adrenoceptor | ADRB2, ADRB3, ADRB1 | MEN1 2819/4885KMT2A 2573/4885PKM 1839/4885 |
| US-20210284617-A1 | Synthesis of (S)-2-Amino-4-Methyl-((R)-2-Methyloxirane-2-Yl)-Pentan-1-One and Pharmaceutically Acceptable Salts Thereof | EPOR, KDM5A, PSMA5 | MEN1 887/4885KMT2A 98/4885PKM 2243/4885 |
| US-11708341-B2 | Synthesis of (S)-2-amino-4-methyl-((R)-2-methyloxirane-2-yl)-pentan-1-one and pharmaceutically acceptable salts thereof | EPOR, KDM5A, PSMA5 | MEN1 887/4885KMT2A 98/4885PKM 2243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.